Pick a semester and a book — read its full first chapter free, no account needed.
Chapter 1: Drug Discovery and Development
By Sushmita Hiremath, Nikhil Gawas
College of Pharmacy, Belagavi
New drug discovery and development is a complex, multidisciplinary process aimed at identifying and bringing novel therapeutic agents to market. It begins with target identification, followed by lead compound discovery through high-throughput screening and computational modeling. Promising candidates undergo optimization for efficacy, selectivity, and pharmacokinetics.
Preclinical testing in vitro and in vivo assesses safety and biological activity. If successful, the drug enters clinical trials, progressing through Phases I to III to evaluate safety, dosage, efficacy, and side effects in humans. Regulatory approval is sought based on trial data, and post-marketing surveillance ensures long-term safety.
Advances in genomics, artificial intelligence, and personalized medicine are revolutionizing the drug discovery landscape, improving success rates and reducing development time. Despite high costs and risk of failure, innovative strategies and technologies continue to enhance the efficiency and precision of drug development, offering hope for treating a wide range of diseases and unmet medical needs. KEY WORDS - Clinical Trials, Lead Optimization, Pharmacokinetics, Regulatory Approval, Target Identification INTRODUCTION New drug discovery and development is a vital and intricate process at the core of pharmaceutical research, aimed at creating safe and effective medications to treat, prevent, or cure diseases.
This process typically begins with the identification of biological targets involved in a disease, followed by the discovery and optimization of compounds that can interact with those targets.
Once promising candidates are identified, they undergo extensive preclinical testing to assess their safety and efficacy in laboratory and animal models. Successful compounds then move into clinical trials, where they are rigorously evaluated in human subjects across multiple phases. Drug development is highly regulated, requiring approval from authorities such as the FDA or EMA before a new drug can be marketed.
While the process is time-consuming, costly, and often fraught with challenges, advances in biotechnology, genomics, and artificial intelligence are accelerating discovery efforts and improving the likelihood of success in delivering novel therapeutics. Stages of Drug Discovery: The drug discovery process involves several key stages, each critical to developing a safe and effective therapeutic. Here are the main stages: 1.
Target Identification and Validation Goal: Identify a biological molecule (e.g., protein, gene) involved in a disease that can be targeted by a drug. Validation: Ensure the target plays a critical role in the disease process. 2. Hit Identification Methods: High-throughput screening, computational modeling, or natural product screening.
Outcome: Identify chemical compounds ("hits") that interact with the target. 3. Hit to Lead (H2L) Goal: Refine and optimize hit compounds to improve their potency, selectivity, and drug-like properties. Activities: Medicinal chemistry and early safety profiling. 4.
Lead Optimization Focus: Further modify lead compounds to enhance efficacy, reduce toxicity, and improve pharmacokinetics (ADME: Absorption, Distribution, Metabolism, and Excretion). Outcome: Select a candidate for preclinical testing. 5. Preclinical Studies Types: In vitro (cell-based) and in vivo (animal) testing.
Purpose: Assess safety, toxicity, and biological activity before human trials. 6. Investigational New Drug (IND) Application Submitted to: Regulatory agencies (e.g., FDA). Contents: Preclinical data, manufacturing info, and trial protocols. 7.
Clinical Trials Phase I: Safety and dosage (small group of healthy volunteers). Phase II: Efficacy and side effects (larger patient group). Phase III: Confirmation of effectiveness, monitoring of side effects (large-scale trials). 8.
New Drug Application (NDA) / Regulatory Review Purpose: Seek approval to market the drug. Includes: Full data from clinical trials and manufacturing processes. 9. Post-Marketing Surveillance (Phase IV) Focus: Monitor long-term safety, effectiveness, and rare side effects in the general population.
Each stage builds upon the previous one, with rigorous evaluation to ensure that only the most promising and safe compounds progress. Drug Development Process: The drug development process follows drug discovery and involves rigorous testing, regulatory review, and manufacturing steps to ensure a new drug is safe, effective, and ready for public use. It can be divided into the following key stages: 1.
Preclinical Development Objective: Assess safety, toxicity, pharmacokinetics, and pharmacodynamics in lab (in vitro) and animal (in vivo) studies. Outcome: Determine if the drug is safe enough to be tested in humans. Deliverable: Data to support an Investigational New Drug (IND) application. 2.
Investigational New Drug (IND) Application Submitted to: Regulatory agencies (e.g., FDA in the U.S.). Includes: Preclinical data, manufacturing information, and clinical trial plans. Purpose: Obtain approval to begin human trials. 3.
Clinical Development (Human Trials) Phase I (Safety and Dosage) Participants: 20–100 healthy volunteers. Focus: Evaluate safety, tolerability, and pharmacokinetics. Phase II (Efficacy and Side Effects) Participants: 100–300 patients.
Focus: Assess effectiveness and short-term side effects. Phase III (Confirmation and Comparison) Participants: 1,000–3,000 patients. Focus: Confirm efficacy, monitor adverse reactions, compare with standard treatments.
Outcome: Data used to file a New Drug Application (NDA). 4. New Drug Application (NDA) / Marketing Authorization Submitted to: Regulatory authorities. Includes: All preclinical and clinical data, labeling information, and manufacturing details.
Goal: Gain approval to market the drug. 5. Post-Marketing Surveillance (Phase IV) Purpose: Monitor long-term safety, rare side effects, and real-world effectiveness. May Lead To: Label changes, restrictions, or drug withdrawal if serious risks are identified.
This entire process typically spans 10–15 years and requires significant financial investment and regulatory oversight. Pre-clinical Studies: Preclinical studies are a critical stage in the drug development process that occur before a new drug is tested in humans. The main goal is to evaluate the safety, biological activity, and pharmacological profile of a drug candidate through laboratory and animal testing.
Objectives of Preclinical Studies:
effects (e.g., mechanism of action, target interaction). Secondary Pharmacodynamics: Assess off-target effects to predict potential side effects. 2. Pharmacokinetics (PK) and ADME Studies Study the Absorption, Distribution, Metabolism, and Excretion of the drug.
Helps predict behavior of the drug in humans. 3. Toxicology Studies Evaluate potential harmful effects at different doses and durations. Acute Toxicity: Effects after a single dose.
Sub-chronic and Chronic Toxicity: Effects from repeated dosing. Genotoxicity: Potential to cause DNA damage. Carcinogenicity: Risk of cancer (usually long-term).
Reproductive/Developmental Toxicity: Impact on fertility, embryo, or fetus. 4. Safety Pharmacology Examine effects on vital systems such as: Cardiovascular (e.g., heart rhythm) Respiratory Central Nervous System (CNS) 5. Formulation Development Develop the physical and chemical formulation of the drug for testing (e.g., tablet, injection).
Ensure stability and bioavailability. 6. Good Laboratory Practice (GLP) Compliance Ensure all non-clinical studies are performed under strict quality and regulatory standards. 7. Bioanalytical Method Development Create validated methods to measure drug levels in biological samples (e.g., blood, plasma).
Purpose of Non-Clinical Activities: Establish a safety profile before human exposure. Support regulatory filings (IND, CTA). Guide dose selection for clinical trials.
Non-clinical activities form the scientific foundation for determining whether a new drug is ready for clinical development and eventual human testing. Clinical Studies: Clinical studies, also known as clinical trials, are research studies conducted in human participants to evaluate the safety, efficacy, and optimal use of a new drug or treatment. These studies are essential for obtaining regulatory approval to market the drug.
Objectives of Clinical Studies: Evaluate safety and tolerability in humans. Determine effective dosage ranges. Assess therapeutic efficacy in target populations.
Identify side effects and potential risks. Phases of Clinical Studies: Phase I – Safety and Dosage Participants: 20–100 healthy volunteers (or sometimes patients). Focus: Safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD).
Goal: Find a safe dosage range and identify side effects. Phase II – Efficacy and Side Effects Participants: 100–300 patients with the target disease. Focus: Evaluate drug effectiveness and continue safety assessment.
Goal: Determine optimal dose and gather preliminary efficacy data. Phase III – Confirmation and Comparison Participants: 1,000–3,000+ patients. Focus: Confirm effectiveness, monitor side effects, and compare with existing treatments.
Goal: Provide comprehensive data for regulatory approval (e.g., NDA or BLA). Phase IV – Post-Marketing Surveillance After Approval Focus: Monitor long-term effectiveness and rare or long-term side effects in the general population. Goal: Ensure ongoing safety and evaluate drug performance in real-world settings.
Key Features of Clinical Studies: Must follow Good Clinical Practice (GCP) guidelines. Require ethical approval (e.g., Institutional Review Board or Ethics Committee). Involve informed consent from participants.
May be randomized, double-blind, and placebo-controlled to reduce bias. Clinical studies are critical for translating promising drug candidates into safe and effective treatments for public use. Innovator and Generic Drugs: In the pharmaceutical industry, drugs are broadly classified into innovator (brand-name) drugs and generic drugs.
Both types serve vital roles in healthcare, but they differ significantly in development, cost, and regulatory pathways. 1. Innovator Drugs (Brand-Name Drugs) Definition: An innovator drug is the original product developed and marketed by a pharmaceutical company after extensive research, development, and clinical trials. Key Features: New chemical entity (NCE) with original formulation.
Protected by patents and exclusivity rights. Undergoes full drug discovery and clinical development process. Usually more expensive due to R&D costs.
Example: Lipitor (atorvastatin) developed by Pfizer. 2. Generic Drugs Definition: A generic drug is a copy of an approved innovator drug, introduced after the brand-name drug's patent expires. Key Features: Must contain the same active ingredient, strength, dosage form, and route of administration as the innovator.
Demonstrates bioequivalence (same therapeutic effect). No need for full clinical trials, only bioequivalence studies. Much cheaper due to lower development costs.
Example: Atorvastatin (generic version of Lipitor). Table 1: Regulatory Aspects Aspect Innovator Drug Generic Drug Development Time 10–15 years 1–3 years Cost Billions (due to R&D and trials) Millions (mainly for bioequivalence) Approval Pathway New Drug Application Abbreviated New Drug Application Clinical Trials Required? Yes (all phases I–III) No (only bioequivalence studies) Importance of Both: Innovator drugs drive innovation and address unmet medical needs.
Generics improve affordability and access to essential medicines once patents expire. Together, they balance innovation and cost-effectiveness in the healthcare system. Concept of Generics: Generic drugs are pharmaceutical products that are equivalent to brand-name (innovator) drugs in dosage form, strength, route of administration, quality, performance characteristics, and intended use.
They are introduced after the patent protection of the innovator drug expires, making treatment more affordable and accessible. Key Characteristics of Generic Drugs: Same Active Ingredient: Generic drugs contain the same chemical substance as the innovator drug. Example: Paracetamol in both Tylenol (brand) and generic versions.
Bioequivalence: Generics must demonstrate bioequivalence, meaning they work in the same way and provide the same clinical benefit as the brand-name drug. Assessed through pharmacokinetic studies (e.g., Cmax, AUC). Different Inactive Ingredients: Fillers, colors, or preservatives may differ, but these must not affect safety or efficacy.
Lower Cost: Generics are typically 80–90% cheaper than brand-name drugs because they do not repeat expensive R&D or clinical trials. Regulatory Approval: Approved through an Abbreviated New Drug Application (ANDA). No need for full clinical trials—only bioequivalence data is required.
Benefits of Generic Drugs: Affordability: Lower prices make essential medications accessible to more people. Quality and Safety: Must meet the same quality standards as brand-name drugs. Healthcare Savings: Widely used in public health systems to reduce spending.
Generic Drug Product Development: Generic drug product development refers to the process of creating a pharmaceutical product that is equivalent to a previously approved brand-name drug in terms of active ingredient, dosage form, strength, route of administration, and therapeutic effect. The goal is to provide an affordable, accessible, and safe alternative to the innovator drug once its patent expires. Key Steps in Generic Drug Development: 1.
Understanding the Innovator Drug Identify the Reference Drug: Select the innovator drug whose patent has expired and which will serve as the reference for the generic version. Study the Brand-Name Drug’s Properties: This includes the active pharmaceutical ingredient (API), formulation, stability, and pharmacokinetic profile. 2. Formulation Development Active Ingredient: Use the same active ingredient(s) as the innovator drug.
Excipients: While the excipients (inactive ingredients like fillers, binders, and preservatives) may differ from the original, they must not affect the drug’s safety, effectiveness, or stability. Dosage Form: Develop the same dosage form (e.g., tablet, capsule, injectable) and similar physical characteristics (e.g., color, size) as the reference drug. 3. Preformulation Studies These studies help to determine the physicochemical properties of the active ingredient (e.g., solubility, stability) and identify potential formulation issues.
Conduct compatibility testing between the active ingredient and excipients to avoid stability or efficacy problems. 4. Bioequivalence Studies Bioequivalence is the key criterion for approval of a generic drug. Pharmacokinetic Testing: Compare the rate and extent of absorption of the generic drug with the reference drug in a controlled, clinical setting.
Parameters Measured: Cmax (maximum concentration), Tmax (time to reach maximum concentration), and AUC (area under the curve). The generic must show no significant differences in these parameters compared to the reference drug. 5. Stability StudiesEvaluate the stability of the generic drug under various conditions (e.g., temperature, humidity) over time.
Ensure the product maintains its safety, efficacy, and quality during its shelf life. 6. Manufacturing Process Develop a scalable manufacturing process that ensures consistent quality, efficacy, and uniformity of each batch. Manufacturing must comply with Good Manufacturing Practice (GMP) regulations to meet safety and quality standards. 7.
Regulatory Approval (ANDA Submission) Once development is complete, submit an Abbreviated New Drug Application (ANDA) to regulatory authorities like the FDA (Food and Drug Administration) or EMA (European Medicines Agency). The ANDA includes: Proof of bioequivalence. Full manufacturing and quality control details.
Stability data. Labeling information. 8. Post-Marketing SurveillanceAfter the generic drug is launched, continue to monitor its safety and efficacy in the general population.
Phase IV monitoring helps identify rare side effects and long-term outcomes. Challenges in Generic Drug Development: Bioequivalence Testing: The need for thorough and rigorous bioequivalence studies to ensure therapeutic equivalence can be costly and time-consuming. Formulation Differences: Minor differences in excipients or manufacturing processes might affect bioavailability.
Intellectual Property Concerns: Navigating patents and exclusivity periods to ensure freedom to operate. Benefits of Generic Drug Development: Cost Reduction: Generics are typically 80–90% cheaper than brand-name drugs, helping to lower healthcare costs. Improved Access: Widespread availability of generics improves patient access to essential medications.
Market Competition: Increased availability of generics fosters competition and helps control prices in the pharmaceutical market. CONCLUSION: The process of new drug discovery and development is a highly complex, resource-intensive journey that requires collaboration across multiple scientific disciplines, including chemistry, biology, pharmacology, and clinical research. From the initial identification of disease targets to the rigorous preclinical testing and clinical trials, each phase is critical to ensuring the safety, efficacy, and therapeutic benefit of new drugs.
Despite its high costs and the inherent risks of failure, advancements in technology, biotechnology, and personalized medicine continue to accelerate the development of novel therapies. Moreover, the rise of computational tools, artificial intelligence, and genomics is reshaping how drugs are discovered and optimized, leading to more efficient and precise solutions for various diseases. The integration of innovative strategies and advanced technologies holds the potential to transform how diseases are treated, offering hope for previously unmet medical needs.
Ultimately, the goal of new drug discovery and development is not just to create novel medications, but to significantly improve quality of life , extend life expectancy , and address public health challenges on a global scale. With ongoing research, regulatory rigor, and collaborative efforts, the future of drug development holds great promise in advancing healthcare for people worldwide. REFERENCES: 1.
Wermuth, C. G. (2011).
The Practice of Medicinal Chemistry (3rd ed.). Elsevier. 2. Ather, S., & Ali, S.
(2020). "Advances in Drug Discovery and Development: A Review." Journal of Drug Design and Medicinal Chemistry , 6(3), 47-52. 3. DiMasi, J. A., & Grabowski, H.
G. (2018). "The Cost of Biopharmaceutical R&D: Is Biotech Different?" Managerial and Decision Economics , 39(2), 168-179. 4. Hughes, J.
P., et al. (2011). "Principles of Early Drug Discovery." British Journal of Pharmacology , 162(6), 1237–1249. 5. Lodish, H., et al.
(2016). Molecular Cell Biology (8th ed.). W.H.
Freeman and Company. 6. Vasudevan, M., & Manickam, G. (2019). "Challenges in Drug Discovery and Development." Pharmaceutical Medicine , 33(2), 121–134. 7.
FDA (2020). New Drug Application (NDA) Process . U.S.
Food and Drug Administration. https://www.fda.gov/drugs/new-drug-application-nda
This preview stops at Chapter 1. Sign up to unlock full chapters, quizzes, and progress tracking.